Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity1

The phenomenon of concomitant tumor immunity involves a tumor-bearing host rejecting another similar tumor at a distant site and suggests the existence of tumor-specific immunity. Loss of this immunity may contribute to tumor metastasis. However, mechanisms underlying the loss of concomitant immunity are largely unknown. We set up a concomitant tumor immunity model in which this immunity is gradually lost as the primary tumor progresses. We found that CD8+ T cells, especially tumor-infiltrating CD8+ T cells, from mice that lost concomitant tumor immunity, possessed potent antitumor properties and strongly expressed effector molecules. Furthermore, effector/memory regulatory T cells (Treg cells, CD103+CD4+Foxp3+ T cells) increased as the primary tumor progressed. They initially accumulated around the tumor and in the spleen at later points. Not only did these cells more greatly express killing molecules, they also suppressed the functions of tumor-bearing CD8+ T cells in vitro and in vivo. Finally, we show that these effector/memory Treg cells inhibit concomitant tumor immunity in vivo. Taken together, data suggest that effector/memory Treg cells are responsible for the loss of concomitant tumor immunity associated with tumor progression.

[1]  Howard,et al.  Collected studies on immunity , 2009 .

[2]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[3]  Qizhi Tang,et al.  The Foxp3+ regulatory T cell: a jack of all trades, master of regulation , 2008, Nature Immunology.

[4]  F. Marincola,et al.  Tumour immunity: effector response to tumour and role of the microenvironment , 2008, The Lancet.

[5]  T. Yi,et al.  In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. , 2007, Blood.

[6]  T. Ley,et al.  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. , 2007, Immunity.

[7]  I. Sheen,et al.  Liver injury is associated with enhanced regulatory T‐cell activity in patients with chronic hepatitis B , 2007, Journal of viral hepatitis.

[8]  A. Rudensky,et al.  Altering the distribution of Foxp3+ regulatory T cells results in tissue-specific inflammatory disease , 2007, The Journal of experimental medicine.

[9]  E. Shevach,et al.  Distinct Subsets of FoxP3 Regulatory T Cells Participate in the Control of Immune Responses , 2007 .

[10]  T. Curiel,et al.  Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.

[11]  S. Hirohashi,et al.  FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis , 2007, Clinical Cancer Research.

[12]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Y. Belkaid,et al.  CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence , 2006, The Journal of experimental medicine.

[14]  A. Frey,et al.  Effector‐phase tolerance: another mechanism of how cancer escapes antitumor immune response , 2006, Journal of leukocyte biology.

[15]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  F. Powrie,et al.  Essential role for CD103 in the T cell–mediated regulation of experimental colitis , 2005, The Journal of experimental medicine.

[17]  Manuela Gariboldi,et al.  Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Old,et al.  CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. , 2005, Blood.

[19]  Y. Belkaid,et al.  A Role for CD103 in the Retention of CD4+CD25+ Treg and Control of Leishmania major Infection1 , 2005, The Journal of Immunology.

[20]  M. Dorf,et al.  Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor , 2005, The Journal of experimental medicine.

[21]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[22]  Youjin Lee,et al.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors , 2005, The Journal of experimental medicine.

[23]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .

[24]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[25]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[26]  J. Buer,et al.  Developmental Stage, Phenotype, and Migration Distinguish Naive- and Effector/Memory-like CD4+ Regulatory T Cells , 2004, The Journal of experimental medicine.

[27]  Y. Belkaid,et al.  CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity , 2002, Nature.

[28]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[29]  Ethan M. Shevach,et al.  CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.

[30]  Hiroshi Tanaka,et al.  Depletion of CD4+CD25+ Regulatory Cells Augments the Generation of Specific Immune T Cells in Tumor-Draining Lymph Nodes , 2002, Journal of immunotherapy.

[31]  T. Tüting,et al.  Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. , 2001, Cancer research.

[32]  A. Frey,et al.  CD8+ Tumor-Infiltrating T Cells Are Deficient in Perforin-Mediated Cytolytic Activity Due to Defective Microtubule-Organizing Center Mobilization and Lytic Granule Exocytosis , 2001, The Journal of Immunology.

[33]  D. Pardoll Stress, NK Receptors, and Immune Surveillance , 2001, Science.

[34]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[35]  R. Offringa,et al.  Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine , 2001, The Journal of experimental medicine.

[36]  A. Frey,et al.  CD8+ Tumor-Infiltrating Lymphocytes Are Primed for Fas-Mediated Activation-Induced Cell Death But Are Not Apoptotic In Situ1 , 2001, The Journal of Immunology.

[37]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[38]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[39]  E. Jaffee,et al.  Cancer Vaccines , 1997, Current protocols in human genetics.

[40]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[41]  R. North,et al.  T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity [published erratum appears in J Exp Med 1986 Dec 1;164(6):2131] , 1986, The Journal of experimental medicine.

[42]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[43]  I. Bursuker,et al.  Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells , 1984, The Journal of experimental medicine.

[44]  R. North,et al.  The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity , 1978, The Journal of experimental medicine.

[45]  S. Howell,et al.  Defects in cell‐mediated immunity during growth of a syngeneic simian virus‐induced tumor , 1975, International journal of cancer.

[46]  P. Deckers,et al.  The adoptive transfer of concomitant immunity to murine tumor isografts with spleen cells from tumor-bearing animals. , 1971, Cancer research.

[47]  E. F. Bashford FOURTH SCIENTIFIC REPORT OF THE INVESTIGATIONS OF THE IMPERIAL CANCER RESEARCH FUND , 1912 .

[48]  A. Moreira,et al.  Systemic and Local Characterization of Regulatory T Cells in a Chronic Fungal Infection in Humans , 2006 .

[49]  J. Serody,et al.  Cells during Acute Graft-versus-host Disease Regulatory T + Cd25 + Critical Role for Ccr5 in the Function of Donor Cd4 , 2005 .

[50]  C. Griscelli,et al.  A monoclonal antibody (HML‐1) defining a novel membrane molecule present on human intestinal lymphocytes , 1987, European journal of immunology.